Since the advent of PSA screening in the early 1990s, prostate cancer mortality in the U.S. has decreased by almost 50% [2,3,4], and today PSA remains the principal marker used for detection, progression, and, in certain contexts, predicting the clinical outcomes of prostate cancer [5,6]. Here, KLK3 is linked to prostate cancer.